Cetuximab combination with cytokine induced killer cells effectively inhibit conjunctival squamous cell carcinoma in vitro
Open Access
- 10 July 2026
- journal article
- Published by Springer Nature in BMC Immunology
- Vol. 27 (1)
Abstract
We explored the potential effects of the anti-EGFR monoclonal antibody Cetuximab when combined with activated cytokine-induced killer cells (CIKs) as a novel treatment strategy for human conjunctival squamous cell carcinoma (CSCCs) in vitro. The CSCC used in our study was obtained from an explant of a patient diagnosed with the condition. After molecular and pathological confirmations, the CSCC was established as proliferating and confluent cultures and was exposed continuously for seven days to different concentrations of Cetuximab (10-3-103 µg/mL) and different ratios of CIKs. CIK cells were cultured with a high dose of IL-2 and the cell population contained activated CD3 + , CD16 + , and CD56 + cells. CIK cells alone exhibited cytotoxicity toward EGFR-positive CSCC whereas Cetuximab alone exhibited limited cytotoxic efficacy. Final counts of CSCC measured on days 1 and 7 after exposure demonstrated over 95% suppression of proliferating CSCC at a Cetuximab concentration of 102 µg/mL, with a CIKs ratio of 50:01 (Effector:Target). Meanwhile, the confluent normal limbal stem cells were largely unaffected. This particular anti-EGFR monoclonal antibody could be beneficial in treating proliferative ocular epithelial conditions, including squamous cell carcinoma of the ocular surface.Keywords
Funding Information
- Iran University of Medical Sciences
This publication has 44 references indexed in Scilit:
- Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapyCancer Immunology, Immunotherapy, 2024
- An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancerCritical Reviews in Oncology/Hematology, 2023
- Cord blood–derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumorsCytotherapy, 2018
- Pathophysiology of ocular surface squamous neoplasiaExperimental Eye Research, 2014
- Surgical versus Medical Treatment of Ocular Surface Squamous NeoplasiaOphthalmology, 2014
- Risk Factors for Ocular Surface Squamous Neoplasia Recurrence after Treatment With Topical Mitomycin C and Interferon Alpha-2bAmerican Journal of Ophthalmology, 2014
- Epidermal Growth Factor Receptor Inhibitors for Treatment of Orbital Squamous Cell CarcinomaArchives of Ophthalmology (1950), 2012
- KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell linesJournal of Cancer Research and Clinical Oncology, 2012
- The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesisGraefe's Archive for Clinical and Experimental Ophthalmology, 2012
- Surgical Management of Conjunctival TumorsArchives of Ophthalmology (1950), 1997